We are live on ! Find out more
ZCM

Ziegler Capital Management Portfolio holdings

AUM $2.62B
1-Year Est. Return 34.71%
This Fund
S&P 500
This Quarter Est. Return
-3.63%
1 Year Est. Return
+34.71%
3 Year Est. Return
+56.01%
5 Year Est. Return
10 Year Est. Return
AUM
$2.36B
AUM Growth
-$421M
Cap. Flow
-$272M
Cap. Flow %
-11.52%
Top 10 Hldgs %
17.39%
Holding
443
New
27
Increased
79
Reduced
232
Closed
79

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$21.4M
2
MEDP icon
Medpace
MEDP
+$15.6M
3
STZ icon
Constellation Brands
STZ
+$13.6M
4
AXP icon
American Express
AXP
+$11.7M
5
DRE
Duke Realty Corp.
DRE
+$9.79M

Sector Composition

Rank Sector Weight
1 Technology 17.79%
2 Financials 14.54%
3 Industrials 11.84%
4 Healthcare 11.58%
5 Consumer Discretionary 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UTL icon
326
Unitil
UTL
$977M
$647K 0.03%
12,978
-1,500
-10% -$73.3K
NUE icon
327
Nucor
NUE
$62.3B
$640K 0.03%
4,305
-1,200
-22% -$147K
B
328
DELISTED
Barnes Group Inc.
B
$637K 0.03%
15,856
+6,546
+70% +$293K
AB icon
329
AllianceBernstein
AB
$3.48B
$633K 0.03%
13,465
EGRX
330
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$585K 0.02%
11,823
ANAB icon
331
AnaptysBio
ANAB
$1.68B
$563K 0.02%
22,774
-2,400
-10% -$72.6K
BIG
332
DELISTED
Big Lots, Inc.
BIG
$551K 0.02%
15,935
-3,200
-17% -$126K
CHRS icon
333
Coherus Oncology
CHRS
$184M
$513K 0.02%
39,737
VB icon
334
Vanguard Morningstar Small-Cap ETF
VB
$82.7B
$495K 0.02%
2,328
NWLI
335
DELISTED
National Western Life Group, Inc. Class A
NWLI
$487K 0.02%
2,313
-370
-14% -$79K
DCP
336
DELISTED
DCP Midstream, LP
DCP
$436K 0.02%
12,980
VNDA icon
337
Vanda Pharmaceuticals
VNDA
$298M
$435K 0.02%
38,438
-3,200
-8% -$42.1K
ORCL icon
338
Oracle
ORCL
$417B
$425K 0.02%
5,137
+446
+10% +$36.1K
TRGP icon
339
Targa Resources
TRGP
$57.6B
$411K 0.02%
5,448
SAGE
340
DELISTED
Sage Therapeutics
SAGE
$408K 0.02%
12,326
-1,060
-8% -$39.8K
PAA icon
341
Plains All American Pipeline
PAA
$16.4B
$396K 0.02%
36,772
-373
-1% -$3.99K
BLDR icon
342
Builders FirstSource
BLDR
$7.89B
$388K 0.02%
6,013
-270
-4% -$19.6K
BPMC
343
DELISTED
Blueprint Medicines
BPMC
$377K 0.02%
5,904
PRFT
344
DELISTED
Perficient Inc
PRFT
$376K 0.02%
3,414
-149
-4% -$15.6K
COHU icon
345
Cohu
COHU
$2.44B
$367K 0.02%
12,386
-25,034
-67% -$800K
JNCE
346
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$346K 0.01%
50,946
ANIK icon
347
Anika Therapeutics
ANIK
$281M
$343K 0.01%
13,655
-1,900
-12% -$57.9K
ALTR
348
DELISTED
Altair Engineering Inc
ALTR
$322K 0.01%
+5,005
New +$316K
BRBR icon
349
BellRing Brands
BRBR
$1.33B
$310K 0.01%
+13,435
New +$337K
FOCS
350
DELISTED
Focus Financial Partners Inc. Class A
FOCS
$287K 0.01%
+6,275
New +$315K

Similar funds

Ziegler Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Ziegler Capital Management held 443 positions worth $2.36B, down 15% from $2.78B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Ziegler Capital Management withdrew a net $272M in Q1 2022, closing 79 positions and reducing 232 holdings. Its most notable exit was Medpace, an estimated $15.6M position sold in full.

By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Industrials.

Against the trend, Ziegler Capital Management opened a new position in Valvoline worth $8.67M.

  • Ziegler Capital Management's largest Q1 2022 buy was Valvoline: 274,739 shares worth $8.67M.
  • Ziegler Capital Management added most to Simon Property Group in Q1 2022, an estimated $8.13M increase.
  • Ziegler Capital Management's biggest Q1 2022 reduction was Apple, cutting an estimated $21.4M.
  • Ziegler Capital Management fully exited Medpace in Q1 2022, selling an estimated $15.6M.
  • Ziegler Capital Management's ten largest holdings make up 17% of its $2.36B portfolio in Q1 2022.
  • Ziegler Capital Management opened 27 new positions and closed 79 in Q1 2022.
  • Ziegler Capital Management's portfolio value fell 15% quarter-over-quarter to $2.36B.

Based on Ziegler Capital Management's 13F filing for Q1 2022, filed 4 May 2022.